» Articles » PMID: 32525765

Genetic Cluster Analysis of SARS-CoV-2 and the Identification of Those Responsible for the Major Outbreaks in Various Countries

Overview
Date 2020 Jun 12
PMID 32525765
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

A newly emerged coronavirus, SARS-CoV-2, caused severe pneumonia outbreaks in China in December 2019 and has since spread to various countries around the world. To trace the evolution route and probe the transmission dynamics of this virus, we performed phylodynamic analysis of 247 high quality genomic sequences available in the GISAID platform as of 5 March 2020. Among them, four genetic clusters, defined as super-spreaders (SSs), could be identified and were found to be responsible for the major outbreaks that subsequently occurred in various countries. SS1 was widely disseminated in Asia and the US, and mainly responsible for outbreaks in the states of Washington and California as well as South Korea, whereas SS4 contributed to the pandemic in Europe. Using the signature mutations of each SS as markers, we further analysed 1539 genome sequences reported after 29 February 2020 and found that 90% of these genomes belonged to SSs, with SS4 being the most dominant. The relative degree of contribution of each SS to the pandemic in different continents was also depicted. Identification of these super-spreaders greatly facilitates development of new strategies to control the transmission of SARS-CoV-2.

Citing Articles

Evolution of a Distinct SARS-CoV-2 Lineage Identified during an Investigation of a Hospital Outbreak.

Choi H, Hwang M, Cornelius L, Navarathna D, Chatterjee P, Jinadatha C Viruses. 2024; 16(3).

PMID: 38543703 PMC: 10974601. DOI: 10.3390/v16030337.


A Tale of Two Proteases: M and TMPRSS2 as Targets for COVID-19 Therapies.

Farkas B, Minneci M, Misevicius M, Rozas I Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375781 PMC: 10301481. DOI: 10.3390/ph16060834.


Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.

Lazarus R, Querton B, Ramljak I, Dewasthaly S, Jaramillo J, Dubischar K Lancet Infect Dis. 2022; 22(12):1716-1727.

PMID: 36075233 PMC: 9444237. DOI: 10.1016/S1473-3099(22)00502-3.


Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview.

Hadizadeh N, Naderi M, Khezri J, Yazdani M, Shamsara M, Hashemi E J Diabetes Metab Disord. 2022; 21(2):1763-1783.

PMID: 35891981 PMC: 9305048. DOI: 10.1007/s40200-022-01002-6.


Exploring the dynamic variations of viral genomes via a novel genetic network.

Zhang Y, Wen J, Xi K, Pan Q Mol Phylogenet Evol. 2022; 175:107583.

PMID: 35810971 PMC: 9262653. DOI: 10.1016/j.ympev.2022.107583.


References
1.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

2.
Letunic I, Bork P . Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 2016; 44(W1):W242-5. PMC: 4987883. DOI: 10.1093/nar/gkw290. View

3.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

4.
Sagulenko P, Puller V, Neher R . TreeTime: Maximum-likelihood phylodynamic analysis. Virus Evol. 2018; 4(1):vex042. PMC: 5758920. DOI: 10.1093/ve/vex042. View

5.
Forster P, Forster L, Renfrew C, Forster M . Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020; 117(17):9241-9243. PMC: 7196762. DOI: 10.1073/pnas.2004999117. View